Avacta Group Share News (AVCT)

Avacta Signs Licensing Agreement To Develop Therapies For Drug Resistant Infections

Avacta Launches Blood Analysis System In UK Veterinary Practices

Thursday broker round-up UPDATE

African Barrick Gold: Deutsche Bank ups target price from 137p to 145p and maintains a hold recommendation. African Minerals: Macquarie reduces target price from 307p to 280p and reiterates an outperform rating. Deutsche Bank cuts target price from 450p to 423p, while its buy recommendation is kept

Avacta Appoints New R&D Chief For Affimer Antibodies Alternative

Tuesday broker round-up UPDATE

Alent: Credit Suisse lowers target price from 430p to 420p keeping an outperform rating. UBS ups target price from 350p to 365p and maintains a neutral rating. Anglo American: Jefferies cuts target price from 1700p to 1650p and maintains a hold recommendation. Aquarius Platinum: RBC Capital shifts

Thursday broker round-up UPDATE

Alkane Energy: Liberum Capital initiates with a target price of 44p and a buy recommendation. Anite: Panmure Gordon shifts target price from 170p to 171p and maintains a buy recommendation. Atkins: Credit Suisse raises target price from 770p to 822p, but downgrades to underperform. Avacta Group:

Avacta Group widens half-year losses as sales slow

Animal and human healthcare company Avacta Group widened its half-year losses as revenues slowed during the introduction of new Optim analytical devices. The provider of analytical and diagnostic technologies to the pharmaceutical and animal healthcare sectors, posted an operating loss of £0.97m i

Avacta Group bullish on outlook

Diagnostic technology provider Avacta Group posted a jump in 12-month revenues and predicted substantial progress over the coming financial year. Group revenue grew 28% to £3.13m, but saw its operating loss widen to £1.64m, from £1.13m the year before. This amounted to a loss per share of 0.04p, u

Tuesday broker round-up

Aggreko: UBS cuts target from 2,750p to 2,550p, buy rating kept. ARM Holdings: Investec keeps buy rating and 800p target. Avacta: Panmure Gordon keeps buy rating and 1.75p target. AZ Electronic: Canaccord Genuity ups target from 360p to 376p, buy rating kept. Babcock: JPMorgan Cazenove ups targe

Friday broker round-up - UPDATE

Aggreko: Jefferies keeps buy rating and 2,800p target; Seymour Pierce keeps buy rating and 2,500p target; Panmure Gordon cuts target from 2,228p to 2,159p, hold rating unchanged. Alliance Pharma: umps upgrades to buy, target lifted from 32p to 37p. Avacta: Panmure Gordon keeps buy rating and 1.75p

Contracts round-up: GETECH, Norcon, Avacta

GETECH, the oil services business specialising in the provision of exploration data and geological exploration studies, has announced a new call-off contract, valued at one million euro, with a major existing client. The order includes a committment to GETECH's Global Programmes, as well as purchase

Avacta poised for growth

Diagnostic tests and testing equipment supplier Avacta continues its steady progress towards break-even but it would have been a step or two closer but for some manufacturing issues which delayed the release of a new product. Revenue in the six months to the end of January shot up to £1.72m from £1

London close: Footsie hits nine-day high after economic data

The Footsie held on to gains by the close, helped by some helpful economic data at home and abroad. It seems as if the 'Santa rally' that many had put on their Christmas lists has finally started to bear fruit with London's blue chip index finished at the highest closing level since last Tuesday. B

London midday: Stocks higher after GDP data

Gains were bolstered by midday on the FTSE 100 with some better-than-expected GDP data helping to boost sentiment. Financials were among the high risers of the day, with Schroders, Lloyds, RBS and Old Mutual among the best performers. UK gross domestic product (GDP) grew by 0.6% in the third quarte

London open: Banks spearhead unhurried advance

If Footsie is to show a gain on the year, it needs to add about 600 points between now and the close of play on December 30th and though the top-share index has made modest inroads into that deficit this morning, helped by the strength of banks, it is looking increasingly likely that 2011 will be a